Description: Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Home Page: www.chromocell.com
4400 Route 9 South
Freehold,
NJ
07728
United States
Phone:
877 265 8266
Officers
| Name | Title |
|---|---|
| Mr. Francis Knuettel II, M.B.A. | President, CEO, CFO, Treasurer, Secretary & Director |
| Dr. Eric Lang M.D. | Chief Medical Officer |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.1077 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-02-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |